Response letter to "Use, response and outcomes of second-line chemotherapy in patients with advanced biliary tract cancers"

被引：0
|
作者：
Ichimura, Takenori [1 ,2 ]
机构：
[1] Univ Sch Pharm, Dept Hosp Pharmaceut, Tokyo, Japan
[2] Showa Univ, Dept Hosp Pharmaceut, Sch Pharm, 1-5-8 Hatanodai,Shinagawa Ku, Tokyo 1428555, Japan
来源：
JOURNAL OF ONCOLOGY PHARMACY PRACTICE | 2023年 / 29卷 / 04期
关键词：
GEMCITABINE; CISPLATIN;
D O I：
10.1177/10781552231165235
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1025 / 1026
页数：2
相关论文
共 50 条
  • [1] Use, response and outcomes of second-line chemotherapy in patients with advanced biliary tract cancers
    Mathers, Brittney
    Abadi, Shirin
    Davies, Janine M.
    McIntyre, Connor
    Ho, Cheryl
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2022, : 1381 - 1386
  • [2] Response to letter to the editor: Use, response and outcomes of second line chemotherapy in patients with advanced biliary tract cancers
    Mathers, Brittney
    Abadi, Shirin
    Davies, Janine M.
    McIntyre, Connor
    Ho, Cheryl
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (04) : 1027 - 1027
  • [3] Response to letter 'Outcome of second-line chemotherapy for biliary tract cancer'
    Walter, Thomas
    Horgan, Anne M.
    McNamara, Mairead
    McKeeve, Liz
    Min, Trisha
    Hedley, David
    Serra, Stefano
    Krzyzanowska, Monika K.
    Chen, Eric
    Mackay, Helen
    Feld, Ronald
    Moore, Malcolm
    Knox, Jennifer J.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 (06) : 1512 - 1513
  • [4] Second-line chemotherapy in patients with advanced biliary tract cancer
    Takahara, Naminatsu
    Nakai, Yousuke
    Isayama, Hiroyuki
    Sasaki, Takashi
    Ishigaki, Kazunaga
    Saito, Kei
    Mizuno, Suguru
    Kogure, Hirofumi
    Tada, Minoru
    Koike, Kazuhiko
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [5] Second-line therapies in advanced biliary tract cancers
    Tella, Sri Harsha
    Kommalapati, Anuhya
    Borad, Mitesh J.
    Mahipal, Amit
    LANCET ONCOLOGY, 2020, 21 (01): : E29 - E41
  • [6] Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes
    Lowery, Maeve A.
    Goff, Laura W.
    Keenan, Bridget P.
    Jordan, Emmet
    Wang, Rui
    Bocobo, Andrea G.
    Chou, Joanne F.
    O'Reilly, Eileen M.
    Harding, Ames J.
    Kemeny, Nancy
    Capanu, Marianela
    Griffin, Ann C.
    McGuire, Joseph
    Venook, Alan P.
    Abou-Alfa, Ghassan K.
    Kelley, Robin K.
    CANCER, 2019, 125 (24) : 4426 - 4434
  • [7] Second-line FOLFOX chemotherapy for advanced biliary tract cancer
    Lamarca, Angela
    Palmer, Daniel H.
    Wasan, Harpreet Singh
    Ross, Paul J.
    Ma, Yuk Ting
    Arora, Arvind
    Falk, Stephen
    Gillmore, Roopinder
    Wadsley, Jonathan
    Patel, Kinnari
    Anthoney, Alan
    Maraveyas, Anthony
    Iveson, Tim
    Waters, Justin S.
    Hobbs, Claire
    Barber, Safia
    David Ryder, W.
    Ramage, John
    Davies, Linda M.
    Bridgewater, John A.
    Valle, Juan W.
    LANCET ONCOLOGY, 2021, 22 (07): : E288 - E289
  • [8] Capecitabine and cisplatin as a second-line chemotherapy for patients with advanced biliary tract cancer
    Shin, Kabsoo
    Lee, In Seok
    Hong, Tae Ho
    Kim, Joori
    Lee, Myung Ah
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [9] Feasibility and potential benefits of second-line chemotherapy in patients with advanced biliary tract cancer
    Walter, Thomas
    Horgan, Anne M.
    McKeever, Elizabeth
    Min, Trisha
    McNamara, Mairead
    Hedley, David W.
    Serra, Stefano
    Krzyzanowska, Monika K.
    Chen, Eric Xueyu
    Mackay, Helen
    Feld, Ronald
    Moore, Malcolm J.
    Knox, Jennifer J.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [10] Benefit of second-line chemotherapy for advanced biliary tract cancer.
    Moik, Florian
    Riedl, Jakob M.
    Winder, Thomas
    Bezan, Angelika
    Rossmann, Christopher
    Szkandera, Joanna
    Kasparek, Anne-Katrin
    Schaberl-Moser, Renate
    Pichler, Martin
    Stoger, Herbert
    Stotz, Michael
    Gerger, Armin
    Posch, Florian
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345